Bank of New York Mellon
APGE icon

Bank of New York Mellon’s Apogee Therapeutics APGE Stock Holding History

Bank of New York Mellon’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Buy
152,815
+26,058
+21% +$2.35M ﹤0.01% 1614
2026
Q1 		$10.7M Buy
126,757
+8,673
+7% +$630K ﹤0.01% 1900
2025
Q4 		$8.91M Buy
118,084
+10,544
+10% +$664K ﹤0.01% 1989
2025
Q3 		$4.27M Sell
107,540
-93,611
-47% -$3.57M ﹤0.01% 2413
2025
Q2 		$8.74M Sell
201,151
-13,080
-6% -$498K ﹤0.01% 1968
2025
Q1 		$8M Buy
214,231
+103,404
+93% +$4M ﹤0.01% 1969
2024
Q4 		$5.02M Sell
110,827
-1,774
-2% -$90.5K ﹤0.01% 2296
2024
Q3 		$6.61M Sell
112,601
-23,146
-17% -$1.11M ﹤0.01% 2147
2024
Q2 		$5.34M Sell
135,747
-1,520
-1% -$73.8K ﹤0.01% 2312
2024
Q1 		$9.12M Buy
137,267
+71,584
+109% +$3.13M ﹤0.01% 2005
2023
Q4 		$1.84M Buy
65,683
+6,023
+10% +$121K ﹤0.01% 2875
2023
Q3 		$1.27M Buy
+59,660
New +$1.31M ﹤0.01% 3032

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.57% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

Bank of New York Mellon's APGE Position: Q2 2026 in Review

Bank of New York Mellon increased its Apogee Therapeutics (APGE) stake by 21% in Q2 2026, buying an estimated $2.35M and bringing the position to 152,815 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1614.

Bank of New York Mellon first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 84 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Bank of New York Mellon held 152,815 shares of Apogee Therapeutics worth $20.3M as of Q2 2026.
  • Bank of New York Mellon bought 26,058 Apogee Therapeutics shares in Q2 2026, an estimated $2.35M.
  • Apogee Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1614 holding.
  • Bank of New York Mellon first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 84 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.